Research
Hormonal
Retatrutide may be superior to dulaglutide in reducing plasma glucose and body weight.
Practitioners may consider retatrutide as a potentially more effective option than dulaglutide for managing diabetes.
StrongQualifiesmedium confidence
Although retatrutide may be superior to the GLP-1 receptor agonist dulaglutide in reducing plasma glucose and body weight.
Why this rating
Based on the phase 1b clinical trial design mentioned in the abstract.
Source
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023
otherCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →